TY - JOUR
T1 - Myeloablative chemotherapy for recurrent aggressive oligodendroglioma
AU - Cairncross, Gregory
AU - Swinnen, Lode
AU - Bayer, Robert
AU - Rosenfeld, Steven
AU - Salzman, Donna
AU - Paleologos, Nina
AU - Kaminer, Lynn
AU - Forsyth, Peter
AU - Stewart, Douglas
AU - Peterson, Kendra
AU - Hu, Wendy
AU - Macdonald, David
AU - Ramsay, David
AU - Smith, Anne
PY - 2000/4
Y1 - 2000/4
N2 - The objective of this study was to ascertain the duration of tumor control and the toxicities of dose-intense myeloablative chemotherapy for patients with recurrent oligodendrogliomas. Patients with previously irradiated oligodendrogliomas, either pure or mixed, that were contrast enhancing, measurable, and behaving aggressively at recurrence were eligible for this study. Only complete responders or major partial responders (75% reduction in tumor size) to induction chemotherapy - either intensive-dose procarbazine, lomustine, and vincristine or cisplatin plus etoposide - could receive high-dose thiotepa (300 mg/m2/day for 3 days) followed by hematopoietic reconstitution using either bone marrow or peripheral blood stem cells. Thirty-eight patients began induction chemotherapy and 20 (10 men, 10 women; median age 46 years; median Karnofsky score 80) received high-dose thiotepa. For the high-dose group, the median event-free, progression-free, and overall survival times from recurrence were 17, 20, and 49 months, respectively. Tumor control in excess of 2 years was observed in 6 patients (30%). Four patients (20%) are alive and tumor free 27 to 77 months (median, 42 months) from the start of induction therapy; however, fatal treatment-related toxicities also occurred in 4 patients (20%). Three patients died as a result of a progressive encephalopathy which, in 2 instances, was accompanied by a wasting syndrome; 1 patient died as a consequence of an intracerebral (intratumoral) hemorrhage. Fatal toxicities occurred in patients with pretreatment Karnofsky scores of 60 or 70. High-dose thiotepa to consolidate response was a disappointing treatment strategy for patients with recurrent aggressive oligodendroglial neoplasms, although several patients had durable responses. Moreover, as prescribed, high-dose thiotepa had significant toxic effects in previously irradiated patients, especially those with poorer performance status.
AB - The objective of this study was to ascertain the duration of tumor control and the toxicities of dose-intense myeloablative chemotherapy for patients with recurrent oligodendrogliomas. Patients with previously irradiated oligodendrogliomas, either pure or mixed, that were contrast enhancing, measurable, and behaving aggressively at recurrence were eligible for this study. Only complete responders or major partial responders (75% reduction in tumor size) to induction chemotherapy - either intensive-dose procarbazine, lomustine, and vincristine or cisplatin plus etoposide - could receive high-dose thiotepa (300 mg/m2/day for 3 days) followed by hematopoietic reconstitution using either bone marrow or peripheral blood stem cells. Thirty-eight patients began induction chemotherapy and 20 (10 men, 10 women; median age 46 years; median Karnofsky score 80) received high-dose thiotepa. For the high-dose group, the median event-free, progression-free, and overall survival times from recurrence were 17, 20, and 49 months, respectively. Tumor control in excess of 2 years was observed in 6 patients (30%). Four patients (20%) are alive and tumor free 27 to 77 months (median, 42 months) from the start of induction therapy; however, fatal treatment-related toxicities also occurred in 4 patients (20%). Three patients died as a result of a progressive encephalopathy which, in 2 instances, was accompanied by a wasting syndrome; 1 patient died as a consequence of an intracerebral (intratumoral) hemorrhage. Fatal toxicities occurred in patients with pretreatment Karnofsky scores of 60 or 70. High-dose thiotepa to consolidate response was a disappointing treatment strategy for patients with recurrent aggressive oligodendroglial neoplasms, although several patients had durable responses. Moreover, as prescribed, high-dose thiotepa had significant toxic effects in previously irradiated patients, especially those with poorer performance status.
UR - http://www.scopus.com/inward/record.url?scp=0034173311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034173311&partnerID=8YFLogxK
U2 - 10.1093/neuonc/2.2.114
DO - 10.1093/neuonc/2.2.114
M3 - Article
C2 - 11303620
AN - SCOPUS:0034173311
SN - 1522-8517
VL - 2
SP - 114
EP - 119
JO - Neuro-oncology
JF - Neuro-oncology
IS - 2
ER -